Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou

publication date: Apr 14, 2022

VectorBuilder, a CDMO based in Chicago, announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. When finished, the site will include 30 production suites designed to manufacture lentivirus, plasmids, messenger RNA, adeno-associated virus, cell lines and other types of viral and non-viral vectors. VectorBuilder says it offers gene therapy delivery services so biopharmas can focus on their candidates instead of developing their own vectors. The new Guangzhou campus, which will take four years to complete, is part of a global expansion. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital